Protein-related Products Product Catalog

To select the appropriate drug concentration and frequency, it is necessary to carefully study the relationship between the drug dosage and the intended effect. If insufficient medication is received, the effect may be minimal or nonexistent, while administering too much of the drug may lead to toxicity or worsening of the patient's condition. Careful dose-response studies to understand the pharmacokinetics and pharmacodynamics of compounds are a crucial step in drug development and rely on quantitative protein analysis techniques that provide accurate measurements of protein levels after varying drug dosages. Simple Western is an ideal platform for dose-response measurements in pharmaceutical development research, equipped with high throughput, speed, sensitivity, and accuracy. It can cut through noise associated with matrix effects commonly seen in ELISA, allowing for the analysis of target abundance and significant changes in target degradation or post-translational modifications. In this webinar, we will guide you on how to utilize isoelectric point and molecular weight measurements in Simple Western for more accurate dose-response measurements across various applications, including pharmacokinetic assays and targeted protein degradation (TPD).

Adeno-associated virus (AAV) is gaining increasing recognition in gene therapy due to its mild immune response, ability to infect a wide range of cells, and overall safety (Naso et al., 2017). However, because delivery vectors are complex, a series of robust analytical approaches are required to ensure proper assembly and packaging before product release. <RNAscope and BaseScope in situ hybridization technology> This introduces the visualization, detection, and quantification of the in vivo distribution of AAV and LV vectors and the expression of introduced genes in preclinical animal models. <Capillary electrophoresis technology> To address industry challenges, the Cell and Gene Therapy Catapult in London has developed advanced analytical platforms for the characterization of AAV vectors: 1) Assay accuracy through the implementation of next-generation technology 2) Standardization and throughput through automation 3) Inline product characterization in closed processes through the development of process analytical technology May 18, 2021 (Tuesday) AM 1:00

Chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcription regulators, as well as through scaffolding functions mediated by several protein-protein interaction domains. Using cell activity assays, including in silico modeling and capillary-based immunodetection assays (ProteinSimple, WES), we developed a chemical degrader for p300/CBP, dCBP-1. We found that dCBP-1 is highly effective at killing multiple myeloma cells and can disable enhancers that promote the expression of the MYC oncogene. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will serve as a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.

We will introduce Jess/Wes, which fully automates the entire process from protein electrophoresis, fixation, antigen-antibody reaction, to detection, in a joint webinar with Eppendorf.